Skip to content
  • Home
  • About Us
  • Pioneering Approach
  • ADC Platform
  • Clinical Trials
  • News and Publications
  • Colaborations
  • Shareholders
  • Contact
  • English
  • Español (Spanish)
  • Home
  • About Us
  • Pioneering Approach
  • ADC Platform
  • Clinical Trials
  • News and Publications
  • Colaborations
  • Shareholders
  • Contact
  • English
  • Español (Spanish)
  • Home
  • About Us
  • Pioneering Approach
  • ADC Platform
  • Clinical Trials
  • News and Publications
  • Colaborations
  • Shareholders
  • Contact
  • English
  • Español (Spanish)
  • Home
  • About Us
  • Pioneering Approach
  • ADC Platform
  • Clinical Trials
  • News and Publications
  • Colaborations
  • Shareholders
  • Contact
  • English
  • Español (Spanish)

ONCOMATRYX

Modulating the tumor microenvironment

Innovation. Eagerness. Hope

More than just a biotech company.
A multidisciplinary team committed to science, medicine and cancer patients.
Find out more about our history

A new avenue to reach metastatic solid tumors

Our founder, Laureano Simón, envisioned a new approach to target tumor resistance to conventional treatments. It was not about fighting the tumor, but understanding and targeting its microenvironment.

In the war on cancer, our battlefield is the tumor stroma.
Learn more about our approach

Our commitment

We are exploring new horizons in the war on cancer. We envision a new era where cancer will be beaten with orchestrated combinations of precision drugs targeting the tumor and its microenvironment.

Together, we are relentlessly pursuing solutions once deemed impossible, bringing hope to patients.
Our values

Clinical trials

If you are an investigator

Explore the progress of our clinical trials. OMTX705 clinical trials began the journey in 2022.

Clinical trials

If you are a patient

Find out why joining a clinical trial.

Clinical trials

KEEP UP TO DATE WITH THE LATEST NEWS

A Spanish drug offers new hope to patients with metastatic cancer

November 20, 2025 No Comments
Read More »

Oncomatryx Biopharma Awarded Prestigious EIC Accelerator Funding to Advance Groundbreaking ADCs

July 14, 2025 No Comments
Read More »
Agenda de Eventos 2025

Agenda de Eventos 2025

February 26, 2025 No Comments
Read More »
Linkedin X-twitter Youtube

This company is capitalized by INNVIERTE, AN INVESTMENT PROGRAM OF CDTI, E.P.E.

Menu
  • About us
  • Pioneering approach
  • Platform
  • Clinical trials
  • News and publications
  • Contact
Legal
  • Cookie policy
  • Terms and conditions
  • Terms of service
Contact us
  • Parque Tecnológico de Bizkaia 801B – 2P
  • 48160 Derio. Bizkaia. SPAIN
  • +34 946 087 037
 
If you prefer, you can send us an email to: info@oncomatryx.com